MIMETAS BV

Their core work

MIMETAS develops and commercializes organ-on-a-chip technology — miniaturized 3D tissue models grown in microfluidic plates (their flagship product, OrganoPlate) that replicate human organ functions for drug screening and disease research. Across H2020, they serve as the in vitro model provider for consortia studying neurodegenerative diseases, liver metabolism, cancer, placental health, and fungal infections. Their platform replaces or reduces animal testing by offering high-throughput, physiologically relevant tissue models that pharmaceutical companies and academic labs use to test drug candidates. As a Leiden-based biotech SME, they sit at the intersection of microfluidics engineering and biomedical research, translating complex biology into standardized, scalable assay platforms.

What they specialise in

How they've shifted over time

In the early H2020 period (2015–2018), MIMETAS focused on establishing their organ-on-chip platform within neuroscience and basic cell biology, contributing to projects on stroke-Alzheimer's overlap (CoSTREAM), Parkinson's (SysMedPD), and cell mechanics (BIOPOL), while also building a presence in MSCA training networks. From 2019 onward, their involvement broadened significantly: they entered brain delivery and BBB modelling (IM2PACT, ENTRAIN), branched into cancer organoids (PRECODE), fungal infection models (FunHoMic), and advanced therapies (ARDAT), while securing their first and only coordinator role with OrganoPlate Graft. The trajectory shows a company that started by validating its platform in neuroscience and is now expanding it across therapeutic areas, moving from niche technology contributor toward a more central platform provider role.

MIMETAS is broadening from neuroscience specialist to general-purpose organ-on-chip platform provider across oncology, infectious disease, and advanced therapies — expect them to be relevant in any consortium needing human tissue models.

How they like to work

MIMETAS almost exclusively joins as a participant (15 of 17 projects), providing their organ-on-chip platform as a specialist technology contribution to larger research consortia. With 210 unique partners across 25 countries, they maintain a wide but non-repeating network — they are a sought-after technology provider rather than a consortium builder. Their single coordinator role (OrganoPlate Graft, an SME Instrument grant) confirms they are comfortable leading when it concerns their core product, but their strength lies in being the in vitro modelling partner that multiple disease-area consortia bring in.

MIMETAS has collaborated with 210 unique partners across 25 countries, reflecting the breadth of disease areas their platform serves. Their network spans major European research hubs, with particularly strong connections to academic medical centers and pharma companies involved in neuroscience and drug development.

What sets them apart

MIMETAS is one of very few European SMEs that both manufactures organ-on-a-chip hardware and actively participates in the research that uses it — they are not just a supplier but a co-developer embedded in the science. Their OrganoPlate platform has been validated across an unusually wide range of disease areas (neurodegeneration, cancer, liver, placenta, infections), giving them cross-therapeutic credibility that most organ-on-chip companies lack. For consortium builders, MIMETAS brings a ready-made, commercially available tissue modelling platform plus the scientific staff to operate it within a project — reducing the risk of technology development delays.

Highlights from their portfolio

• OrganoPlate Graft
  Their only coordinated project (EUR 2.1M, SME Instrument Phase 2), focused on commercializing vascularised organ-on-chip technology — represents the core of their business strategy.
• CoSTREAM
  Large-scale Health project investigating shared mechanisms between stroke and Alzheimer's, where MIMETAS provided in vitro brain models — demonstrates their integration into high-profile clinical research.
• ARDAT
  Their most recent project (2020-2026, EUR 318K), entering the advanced therapies space (gene/cell therapy for rare diseases) — signals their strategic expansion beyond traditional drug screening.